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Summary
Background: Chronic liver diseases are com-
mon in the general population. Drug treatment in
this group may be challenging, as many drugs are
hepatically metabolised and hepatotoxic.
Objectives:We aimed to assess the mortality of
patients with chronic liver disease according to
specific drug exposures and the three laboratory
parameters creatinine, bilirubin and International
Normalised Ratio (INR).
Methods: We conducted a multicentre, 5-year
retrospective cohort study in two tertiary univer-
sity referral hospitals and a secondary referral hos-
pital, using a research database to evaluate the
crude and adjusted mortality.
Results: Of 1159362 individual patients 1.7%
(n = 20158) had chronic liver disease and in this
group 36.8% had unspecified chronic non-alco-
holic liver disease, 30.1% chronic hepatitis C and
11.9% cirrhosis of the liver. 8.4% of patients pre-
sented a diagnosis associated with alcohol. The
4-year survival rates were significantly higher in
the group with the most normal laboratory values
(94.3%) versus 34.5% in the group with elevated
parameters (p <0.001). Overall, drug exposure was
not associated with higher mortality; in adjusted
multivariate analysis the hazard ratio for anti-can-
cer drugs was 2.69 (95% CI 1.32–5.46). Of indi-
vidual drugs, mortality hazard ratios for amiodar-
one, morphine oral, acetazolamide, sirolimus and
lamivudine were 2.46 (95% CI 1.68–3.61), 2.26
(95% CI 1.78–2.86), 2.10 (95% CI 1.19–3.70),
1.81 (95% CI 1.02–3.21) and 1.72 (95% CI 1.17–
2.53) respectively.
Conclusions: Drug exposure in general was not
associated with higher mortality except for a few
categories.Mortality in patients with chronic liver
disease was high and is associated with simple lab-
oratory values.
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Abbreviations
BBW Black box warning for hepatotoxicity by FDA.
CI Confidence interval
CLD Chronic Liver Disease
D+ Drug exposure group
D- Group with no drug exposure to hepatotoxic drugs
FDA Food and Drug Administration
HR Hazard ratio
INR International Normalised Ratio
L0 Group with all three laboratory values (bilirubin,
INR, creatinine) within normal limits
L1-2 Group with 1 or 2 laboratory parameters above
threshold
L3 Group with all three laboratory parameters above
threshold
MELD Model for End-Stage Liver Disease
Metabolism Flow-dependent hepatic metabolism drug group
LMR Longitudinal Medical Record
RPDR Research Patient Data Registry
SSA DMF Social Security Administration Death Master File
Tox Direct hepatic toxicity drug group
Introduction
Cirrhosis and other chronic liver diseases
(CLD) are common illnesses in the general popu-
lation and involve additional hospitalisations,
medical treatment and a high mortality rate in af-
fected patients. According to the National Center
for Health Statistics, the age-adjusted death rate
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in 2004 was 9.0/100000 US inhabitants/year dy-
ing of CLD,making it the twelfth leading cause of
death [1].
New models such as the Model for End-Stage
Liver Disease (MELD) have been successfully de-
veloped and implemented to predict life expect-
ancy in patients with liver disease and outcome in
liver transplantation, transjugular intrahepatic
portosystemic shunts, alcoholic hepatitis and ful-
minant hepatic failure caused by acetaminophen
toxicity [2–7].
Drugs may present idiosyncratic or dose-de-
pendent toxicity.Drug-induced liver failure repre-
sents the leading identifiable cause of acute liver
failure in the United States [8, 9].While much of
this toxicity occurs in patients with normal hepatic
function, it is a particular challenge to choose the
correct drug and estimate the specific drug metab-
olism and excretion properties in order to adjust
appropriately to individual liver function in pa-
tients with CLD.
All Patients:
n = 1,159,362
Deceased: 5.6%
Excluded Patients:
n = 1,139,2K4
L1-2
n = 7,322
Deceased: 23.4%
MELD = 1K.36
CLD patients
n = 2K,158
Deceased: 13.K%
MELD = 8.22
LK
n = 12,132
Deceased: 4.2%
MELD = 2.47
LKD-
n = 6,837
Deceased: 5.K%
MELD = 2.92
LKD+
n = 5,295
Deceased: 3.2%
MELD = 2.K7
Metabolism
n = 886
Deceased: 7.3%
MELD = 1.85
Metabolism
n = 147
Deceased: 61.2%
MELD = 19.4K
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Tox
n = 3,767
Deceased: 3.2%
MELD = 1.89
Tox
n = 345
Deceased: 49.6%
MELD = 18.11
BBW
n = 1,379
Deceased: 3.3%
MELD = 2.19
BBW
n = 173
Deceased: 53,2%
MELD = 18.K9
LMR
n = 2,786
Deceased: 3.2%
MELD = 2.21
Abbreviations: BBW = Black Box Warning for hepatotoxicity by FDA. CLD = Chronic Liver Disease. D+ = drug exposure,
D- = no drug exposure. Deceased = relative number of deceased patients in each group during study period. Laboratory
thresholds: Total bilirubin: site 1 >1.2, sites 2&3 >1.K mg/dL; INR: site 1 >1.1, site 3>1.K (site 2: treatment thresholds only);
creatinine: site 1 >1.35, site 2 >1.5, site 3 >1.3 mg/dL. LK = all three within normal limits, L1-2 = 1 to 2 laboratory parame-
ters above threshold, L3 = all three above threshold. LMR = hepatotoxic drugs in Longitudinal Medical Record. MELD =
mean MELD score of patients with computable MELD score in each group. Metabolism = ﬂow dependent hepatic metab-
olism.Tox = direct hepatic toxicity.
LMR
n = 297
Deceased: 51.6%
MELD = 17.19
L3D+
n = 494
Deceased: 54.4%
MELD = 19.17
L3
n = 7K4
Deceased: 58.5%
MELD = 2K.98
L3D-
n = 21K
Deceased: 68.1%
MELD = 25.68
CLD
no warfarin
Laboratory
values above
threshold
Liver toxic
drugs
Liver toxic
drugs
Figure 1
Study design.
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We conducted a retrospective cohort study
using data from the Research Patient Data Regis-
try (RPDR) and the Longitudinal Medical Record
(LMR) at Partners Healthcare, a system of aca-
demic and community hospitals addressing the
following questions: What is the mortality rate of
patients with CLD in general? Is their mortality
affected by administering hepatotoxic drugs?
Does exposure to certain drugs or drug classes,
their MELD score or its single laboratory param-
eters predict mortality?
Methods
Study design
We conducted a retrospective observational cohort
study over five years (from 1 January 2002 to 31 Decem-
ber 2006; fig. 1).The Brigham andWomen’s Hospital In-
stitutional Review Board approved the study.
Study subjects
Study patients were all adult (age 18+) in- and outpa-
tients of two tertiary referral teaching hospitals and one
secondary referral hospital in the greater Boston area.
Subjects were identified using the Research Patient Data
Repository (RPDR), a clinical data warehouse at Partners
Healthcare containing information from over 3.5 million
patients and 600 million patient encounters [10]. Partners
Healthcare system is a non-profit organisation which
consists of its two founding academic hospitals, commu-
nity hospitals and community health centres.
Inclusion criteria
All patients seen during the study period were in-
cluded. The time point of inclusion into the CLD group
was the date in the LMR for one of the diagnoses of CLD
as defined below.
Exclusion criteria
We excluded patients treated with warfarin due to its
influence on INR.
Diagnosis of chronic liver disease (CLD)
Patients with CLD were identified from the RPDR
using ICD-9-CM diagnoses.We included chronic rather
than acute liver diseases to establish a more stable liver
function pattern over time. Diagnostic codes included all
571 codes for chronic liver disease as well as 070.54 for
chronic hepatitis C and 070.32 for chronic hepatitis B. If
multiple liver diagnoses were present we assigned the di-
agnosis as the first specific diagnosis within the observa-
tion period; if the first diagnosis was non-specific (571.4
chronic non-viral hepatitis, 571.8 chronic non-alcoholic
liver disease, 571.9 unspecified chronic liver disease with
no mention of alcohol), we sequentially searched in time
until we found a more specific diagnosis coded.
Validation of data
Diagnoses from RPDR were validated by comparing
them with a random sample of 110 electronic charts in
LMR. From each of 11 groups as defined below, 10 charts
were sampled and validated for identity, diagnosis and
drug exposure. Validity testing showed a correct identity
(name, gender and date of birth) in 99.1% (109/110
charts), a correct diagnosis in 96.4% (106/110) and 100%
accuracy regarding drug exposure (110/110). An accurate
diagnosis was defined as showing objective correlates in
LMR patient charts in radiology, pathology or serology
results.
Definition of cancer diagnoses
Because of the impact of cancer diagnosis on mortal-
ity, we included the presence of any cancer diagnosis dur-
ing the study period as a single binary predictor in the
multivariate regression model including ICD-9 codes
140–239, with the exception of 210–229 “benign neo-
plasm” and 230–234 “carcinoma in situ”, assuming that
these diagnoses would have no substantial impact on mor-
tality within a five-year period.
Exposures, outcomes and their measurement
The primary outcomes were crude and adjusted mor-
tality with and without drug exposure. Covariates for ad-
justment next to drug exposure were age, gender, diag-
noses of liver disease and cancer, the MELD score as well
as its three single laboratory parameters creatinine, bi-
lirubin and INR (fig. 1).To compute the MELD score the
patient had to have all three parameters measured on one
day during the observation period. Regarding the single
laboratory values, the value was entered as a binary vari-
able defined as either normal or above threshold meaning
at least one measurement above normal within the obser-
vation period. Institution-based thresholds were: total
bilirubin: site 1 = 0.2–1.2 mg/dL, site 2 = 0.3–1.0 mg/dL,
site 3 = 0.0–1.0 mg/dL; INR: site 1 = 0.9–1.1, site 2: treat-
ment thresholds only, site 3 = 1.0; creatinine: site 1 = 0.7–
1.35 mg/dL, site 2 = <1.5 mg/dL, site 3 = 0.6–1.3 mg/dL.
The final aim consisted of a mortality risk factor analysis
and developing a prediction model based on this analysis.
Group definitions
Groups L0, L1-2 and L3 were defined by laboratory
parameters (creatinine, bilirubin and INR): group L0 had
at no time parameters above thresholds, L1-2 either one
or two of the three parameters above threshold at some
time and in L3 all three parameters were above thresholds
at least once concurrently or at different times. Groups
L1 and L2 were lumped together because of overlap.
Groups with drug exposure (D+) were classified according
to the drug group exposed to; groups without drug expo-
sure were marked D-.
Drug exposures
Drug exposure groups were selected according to
four distinct criteria: hepatic metabolism (“Metabolism”),
direct liver toxicity (“Tox”), FDA Black Box Warning for
hepatotoxicity group (“BBW”) and hepatotoxic drugs as
defined in the LMR (“LMR”). These four drug classes
each contained between 9 and 43 single drugs or drug
combinations (appendix 1). Additionally, we designated
functional drug classes, based on known hepatotoxic risk
issues: statins, antiepileptics, opiates, anticancer drugs,
immunosuppressants and HIV drugs.
Survival Time
Survival time was computed from the time patients
appeared in RPDR (2002–2006) with a diagnosis of liver
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disease until death or censoring at the end of the observa-
tion period. Vital status data are updated monthly in
RPDR using Social Security and National Death Index
[11, 12].
Model for End Stage Liver Disease (MELD)
The MELD score was computed from the last labo-
ratory data within the observation period (3.8 u log
e
(bi-
lirubin, mg/dL) + 11.2 u log
e
(INR) + 9.6 x log
e
(creati-
nine, mg/dL) +6.4) [7]; all three laboratory parameters
had to be measured on the same day.
Statistical analysis
For the comparison of approximately normal varia-
bles across group (such as MELD score), we used the
t-test to compare means; for categorical variables across
groups, we used Pearson’s chi-square. To compare unad-
justed mortality and survival times across groups (e.g., the
three laboratory groups), we used the log rank test. Sur-
vival distributions were characterised by Kaplan-Meier
curves and the 48-months survival rate. Thresholds of
significance were set at α = 0.05.
Cox regression model for mortality. The Cox propor-
tional hazards regression model included all the clinically
relevant predictors: age, gender, race, laboratory value
groups, MELD score, diagnoses of liver disease and can-
cer, drug exposure to single drugs, drug groups and func-
tional drug classes. The adequacy of the Cox regression
model was assessed with the residual-based method pro-
posed by Lin et al. [13]; the functional forms of each cov-
ariate appeared appropriate, and the proportional hazards
assumption for each covariate was not violated (all good-
ness-of-fit p-values >.05). Single drugs were adjusted in
the same way as the drug groups, except for MELD due
to the low number of patients with single drug exposure
and computable MELD score.
We used the SAS statistical software package for
Windows, version 9.1 (SAS Institute Inc., Cary, NC).
Table 1
Characteristics and demographics of individual patients
Characteristics All patients*
N = 1,159,362
(%)
All CLD patients
n = 20,158
(%)
L0
n = 12,132
(%)
L1-2
n = 7,322
(%)
L3
n = 704
(%)
L0D+
n = 5,295
(%)
L0D-
n = 6,837
(%)
L3D-
n = 210
(%)
L3D+
n = 494
(%)
Age [years], mean † 52.6 50.5 55.4 59.7 50.6 50.4 61.4 59.0
18–19
19,021 (1.6)
‡
115 (0.6) 71 (0.6) 43 (0.6) 1 (0.1) 20 (0.4) 51 (0.7) 0 1 (0.2)
20–29 170,746 (14.7) 1,406 (7.0) 1,040 (8.6) 352 (4.8) 14 (2.0) 455 (8.6) 585 (8.6) 2 (0.9) 12 (2.4)
30–39 218,729 (18.9) 3,021 (15.0) 2,141 (17.6) 836 (11.4) 44 (6.3) 972 (18.4) 1,169 (17.1) 6 (2.9) 38 (7.7)
40–49 217,572 (18.8) 5,689 (28.2) 3,603 (29.7) 1,921 (26.2) 165 (23.4) 1514 (28.6) 2,089 (30.5) 46 (21.9) 119 (24.1)
50–59 199,550 (17.2) 5,460 (27.1) 3,157 (26.0) 2,086 (28.5) 217 (30.8) 1373 (25.9) 1,784 (26.1) 69 (32.9) 148 (30.0)
60–69 150,271 (13.0) 2,709 (13.4) 1,423 (11.7) 1,155 (15.8) 131 (18.6) 660 (12.5) 763 (11.2) 44 (21.0) 87 (17.6)
70–79 105,315 (9.1) 1,343 (6.7) 566 (4.7) 682 (9.3) 95 (13.5) 251 (4.7) 315 (4.6) 33 (15.7) 62 (12.5)
80–89 64,040 (5.5) 384 (1.9) 123 (1.0) 228 (3.1) 33 (4.7) 50 (0.9) 73 (1.1) 8 (3.8) 25 (5.1)
=/>90 14,107 (1.2) 31 (0.1) 8 (0.1) 19 (0.3) 4 (0.6) 0 8 (0.1) 2 (0.9) 2 (0.4)
Total 1,159,351 (100) 20,158 (100) 12,132 (100) 7,322 (100) 704 (100) 5,295 (100) 6,837 (100) 210 (100) 494 (100)
Sex
Female 675,059 (58.2) 9,141 (45.3) 6,435 (53.0) 2,485 (33.9) 221 (31.4) 3168 (59.8) 3,267 (47.8) 55 (26.2) 166 (33.6)
Male 484,305 (41.8) 11,017 (54.7) 5,697 (47.0) 4,837 (66.1) 483 (68.6) 2127 (40.2) 3,570 (52.2) 155 (73.8) 328 (66.4)
Race
Caucasian 759,028 (65.5) 14,085 (69.9) 8,214 (67.7) 5,400 (73.7) 471 (66.9) 3526 (66.6) 4,688 (68.6) 152 (72.4) 319 (64.6)
Hispanic 81,918 (7.1) 2,064 (10.2) 1,375 (11.3) 619 (8.5) 70 (9.9) 814 (15.4) 561 (8.2) 19 (9.1) 51 (10.3)
African American 73,081 (6.3) 1559 (7.7) 816 (6.7) 635 (8.7) 108 (15.3) 398 (7.5) 418 (6.1) 20 (9.5) 88 (17.8)
Asian 33,087 (2.9) 1,025 (5.1) 732 (6.0) 274 (3.7) 19 (2.7) 281 (5.3) 451 (6.6) 5 (2.4) 14 (2.8)
American Indian 847 (0.1) 29 (0.1) 22 (0.2) 7 (0.1) 0 16 (0.3) 6 (0.1) 0 0
Other 30,310 (2.6) 408 (2.0) 268 (2.2) 126 (1.7) 14 (2.0) 113 (2.1) 155 (2.3) 4 (1.9) 10 (2.0)
Not recorded 181,125 (15.6) 988 (4.9) 705 (5.8) 261 (3.6) 22 (3.1) 147 (2.8) 558 (8.1) 10 (4.7) 12 (2.4)
Total 1,159,396 (100) 20,158 (100) 12,132 (100) 7,322 (100) 704 (100) 5,295 (100) 6,837 (100) 210 (100) 494 (100)
Vital status
Alive 1,094,776 17,529 11,626 5,611 292 5128 6,498 67 225
Deceased 64,592 2,629 506 1,711 412 167 339 143 269
Malignancy (%)
§
N/A 7,770 (38.6) 3,328 (27.4) 3,935 (53.7) 507 (72.0) 1,888 (35.7) 1,440 (21.1) 119 (56.7) 388 (78.5)
Total 1,159,368 (100) 20,158 (100) 12,132 (100) 7,322 (100) 704 (100) 5,295 (100) 6,837 (100) 210 (100) 494 (100)
Crude mortality %
(95% CI) during
observation period
5.6
(5.56–
5.64)
13.0
(12.54–
13.46)
4.2
(3.84–
4.56)
23.4
(22.43–
24.37)
58.5
(54.86–
62.14)
3.2
(2.73–
3.67)
5.0
(4.48–
5.52)
68.1
(61.80–
74.40)
54.4
(50.00–
58.79)
*Data accuracy in RPDR ± 3 in de-identified patients. Age at the time of data retrieval; in all other groups age is computed at the time of liver diagnosis.
N/A= not assessed. † Not computable; these patients were not personalized. ‡ Age group 18–19 may contain single patients between 10 and 18 years old.
CI=confidence interval. L0: no laboratory values above threshold, L1-2: 1-2 laboratory values above threshold, L3: three laboratory values above threshold.
D+: exposure to drug groups, D- no exposure to drug groups. § ICD-9-CM codes 140–239 excluding 210–229 “Benign neoplasms” and 230–234 “Carcinoma in
situ”.
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The patient population included 1159362 in-
dividual patients, and 22211 with CLD (1.9%,
table 1).Among patients with CLD, 2052 were ex-
cluded on account of warfarin use during the ob-
servation period; one patient was excluded as he
lacked a unique identifier. The remaining 20158
patients (1.7% of all patients) had a mean age of
52.6 years, and a crude mortality of 5.6% (95%CI
5.56–5.64) during the observation period. In the
three laboratory groups L0, L1-2 and L3 mean
age was 50.5, 55.4 and 59.7 years, respectively;
more patients were male (54.7%; range 47.0–
68.6%). Mean age was similar for the L0D+ and
L0D- groups (50.6 and 50.4 years) and somewhat
higher in laboratory positive groups L3D+ and
L3D- (59.0 and 61.4 years). The crude mortality
rate increased with the number of positive labora-
tory values: group L0 4.2% (95% CI 3.84–4.56),
L1-2 23.4% (95% CI 22.43–24.37) and L3 58.5%
(95% CI 54.86–62.14). Crude mortality rate was
lowest in group L0D+ with 3.2% (95% CI 2.73–
3.67) and highest in L3D- (68.1%, 95%CI 61.80–
74.40).
Chronic hepatitis C was the most common
specific diagnosis according to ICD among pa-
tients with CLD, with a mean prevalence of
30.1% (range among subgroups 5.5–32.9%). The
prevalence of chronic hepatitis B (mean 7.5%,
range 3.3–8.7%) was fairly consistent. The most
frequent non-infectious diagnosis was “other non-
alcoholic liver disease” with mean 36.8% (range
4.7–52.8%), followed by “cirrhosis of liver” with
no mention of alcohol (mean 11.9%; range 5.3–
24.3%) and “alcoholic cirrhosis of liver” in 4.1%
of patients (range 0.6–24.3%). 8.4% of patients
showed a diagnosis associated with alcohol use.
Table 2
Unadjusted 48
months survival rates
and mortality in end
stage liver disease
(MELD) scores.
Group* 48 months
survival rate
[95%CI]
Deaths per
1000 person
months
p-Value
†*
(Deaths per 1000 person
months)
MELD score
Mean [95%CI] (n*)
p-Value
‡
(MELD)
All CLD patients 83.4 [82.7–83.9] 4.5 – 8.22 [8.03–8.41] (9,514) –
L0 94.3 [93.8–94.8] 1.4 L0 vs L3: p <0.001 2.47 [2.36–2.58] (3,484) L0 vs L3:
p <0.001
L1-2 71.2 [69.9–72.4] 8.5 L0 vs L1-2: p <0.001 10.36 [10.11–10.61]
(5,355)
L0 vs L1-2:
p <0.001
L3 34.5 [30.3–38.7] 29.0 – 20.98 [20.00-21.96] (675) –
L0D+ 95.6 [94.8–96.3] 1.0 L0D+ vs L0D-:
p <0.001
L0D+ vs L3D+:
p <0.001
2.07 [1.92-2.22] (1,834) L0D+ vs L0D-:
p <0.001
L0D+ vs L3D+:
p <0.001
L0D- 93.3 [92.6–94.1] 1.6 L0D- vs L3D-:
p <0.001
2.92 [2.76–3.08] (1,650) L0D- vs L3D-:
p <0.001
L3D+
38.7 [33.5–43.8] 24.6
L3D+ vs L3D-:
p <0.001
19.17 [18.06–20.28] (487) L3D+ vs L3D-:
p <0.001
L3D- 24.6 [18.0–31.7] 43.5 – 25.68 [23.84–27.52] (188) –
* Group L1-2 was not analysed regarding drug exposure. **Number of patients with computable MELD score within each group.
†
Log rank test.
‡
T-test.
Table 3
Hazard ratios for drug groups and single drugs.
(all adjusted for age, cancer, liver diagnosis and race)*
Drug group/Single drug name
(Number of patients exposed)
Hazard ratio
[95% CI]
Lab adjusted
hazard ratio
†
[95% CI]
Drug groups
Metabolism drug group (n = 1,033) 2.18 [1.81–2.64] 1.74 [1.45–2.10]
BBW drug group (n = 1,552) 1.47 [1.20–1.80] 1.20 [0.96–1.45]
Hepatotoxic drug group (n = 4,112) 0.91 [0.77–1.06] 0.76 [0.65–0.88]
LMR drug group (n = 3,083) 0.68 [0.57–0.81] 0.58 [0.49–0.68]
Functional drug group
Anticancer drugs (n = 184) 3.49 [2.57–4.75] 3.49 [2.53–4.81]
Single drugs
Cyclosporine oral (immunosuppression) (n = 20) 5.16 [2.58–10.31] 2.30 [0.16–4.56]
Etoposide oral (anticancer) (n = 32) 4.03 [2.40–6.77] 3.55 [2.15–5.87]
Sirolimus (immunosuppression) (n = 22) 3.80 [2.06–7.03] 1.81 [1.02–3.21]
Docetaxel (anticancer) (n = 21) 3.40 [1.81–6.40] 7.53 [3.91–14.48]
Morphine oral (opiate analgesic) (n = 239) 3.10 [2.48–3.87] 2.26 [1.78–2.86]
Amiodarone oral (antiarrhythmic) (n = 81) 2.46 [1.68–3.61] ‡
Acetazolamide (diuretic) (n = 45) 2.10 [1.19–3.70] ‡
Lamivudine (antiviral) (n = 164) 1.72 [1.17–2.53] ‡
Ibuprofen (NSAID) (n = 2,605) 0.60 [0.50–0.72] 0.73 [0.60–0.88]
Metformin (antidiabetic) (n = 816) 0.51 [0.35–0.74] 0.59 [0.41–0.87]
Atorvastatin (lipid lowering) (n = 1,370) 0.44 [ 0.34–0.57] 0.63 [0.48–0.83]
Pravastatin (lipid lowering) (n = 183) 0.34 [0.15–0.76] 0.32 [0.14-0.73]
Azathioprine (antimetabolite) (n = 103) 0.25 [0.11–0.59] 0.22 [0.09-0.51]
Simvastatin (lipid lowering) (n = 580) ‡ 0.57 [0.42–0.78]
* In descending order of hazard; reference group for hazard ratios are patients with no
exposure to drugs. † Additional adjustment for high laboratory values. Containing no patients
from group L1-2. ‡ Variable not significant at p = 0.05. NSAID = non-steroidal anti-inflam-
matory drug.
Results
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We computed the unadjusted 4-year survival
rates and deaths per 1000 person months (table 2).
The 4-year survival rates were significantly higher
in groups with the most normal laboratory values:
L0 showed a 4-year survival rate of 94.3% versus
34.5% in group L3 (p <0.001). Drug-exposed pa-
tients showed significantly higher survival rates:
L0D+ with 95.6% 4-year survival vs L0D- with
93.3% (p <0.001) and L3D+ with 38.7% vs L3D-
with 24.6% (p <0.001). The drug exposure sub-
groups differed significantly (all p <0.001) from
each other: the Tox group (L0 Tox and L3 Tox)
had the highest survival rates with 98.5% (95%CI
98.0–98.8) and 42.4% (95% CI 35.9–48.8%); the
Metabolism groups (L0 Metabolism and L3 Me-
tabolism) had the lowest with 89.7% (95% CI
86.8–92.0%) and 35.4% (95% CI 26.9-43.0).
Since laboratory parameters for MELD could be
obtained only for 47.2% (9514/20 158) of pa-
tients, we compared the hazard ratios of the pa-
tient groups with and without MELD scores re-
garding age, gender, cancer and liver diagnoses,
race and exposure to the four drug groups. Esti-
mated hazard ratios and significance levels for the
above variables were very similar between the
MELD and non-MELD groups.
Adjusted hazard ratios (HR) for drug groups
versus subjects with no drug exposure showed that
of the four drug groups studied HR was highest in
the metabolism drug group (1.83, 95% CI 1.01–
3.30; table 3). The other three groups showed
lower HRs without significance. The functional
drug groups showed a high HR for anti-cancer
drugs (2.69, 95% CI 1.32–5.46). The HRs of the
HIV drug group, immunosuppressants, antiepi-
leptics and statins (HR 0.39, 95% CI 0.08–2.01)
were not significant; the opiate group (morphine
oral and pentazocine) was reduced to morphine
oral, since no patient was treated with pentazoc-
ine. Among single drugs docetaxel and etoposide
had the highest adjusted HRs with 7.53 (95% CI
3.91–14.48) and 3.55 (95% CI 2.15–5.87) respec-
tively, followed by morphine (2.26, 95% CI 1.78–
2.86) and sirolimus (HR = 1.81, 95% CI 1.02–
3.21). Amiodarone (HR = 2.46, 95% CI 1.68–
3.61), acetazolamide (2.10, 95%CI 1.19–3.70) and
lamivudine (1.72, 95%CI 1.17–2.53) showed high
HRs even after adjustment including cancer diag-
noses. Some drugs showed a laboratory-adjusted
HR lower than 1.0: ibuprofen, metformin, ator-
vastatin, pravastatin, azathioprine and simvastatin.
The list of the 44 drugs excluded due to small
sample size (<20 patient exposures) can be ob-
tained from the authors.
The survival curves adjusted for age, liver di-
agnosis, cancer and race are plotted in figure 2: the
more laboratory parameters above threshold, the
higher the mortality (fig. 2a). Overall exposure to
drug groups was not associated with a higher mor-
tality rate (fig. 2b). MELD scores below ten had a
close to identical outcome; the other four strata
showed a regular pattern with an inverse relation-
ship between MELD and survival (fig. 2c).
Figure 2
Survival Curves:
2a Laboratory
Groups; 2b Drug
Exposure Groups; 2c
MELD Score Groups.
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Individual patients
were followed from
inclusion time to time
of death or censoring
at the end of the
observation period
(see Methods
section).
The prevalence of a malignancy diagnosis was
38.6% for all groups, with a range from 21.1% in
group L0D- to 78.5% in group L3D+.
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Our study revealed no association between
overall drug exposure and mortality in patients
with chronic liver disease, although exposure to
certain drug groups such as anti-cancer drugs and
the metabolism drug group was associated with an
almost twofold or higher mortality hazard ratio, as
were five individual drugs (amiodarone,morphine,
acetazolamide, lamivudine and sirolimus). To the
best of our knowledge overall drug exposure and
these drug groups have not been evaluated regard-
ing mortality in a retrospective cohort study of
this size in patients with chronic liver illness.
However, the risk of single drugs has been as-
sessed in many studies.Here our findings are quite
consistent with the literature; for example, amio-
darone has been reported to cause drug-induced
liver injury with fatal outcome by the World
Health Organization Collaborating Centre for
International Drug Monitoring [14]. In addition,
patients with liver illness can develop acetazol-
amide-induced severe lactic acidosis and ketosis
by inhibition of the mitochondrial carbonic anhy-
drase V [15], which has been suspected to cause
bone marrow depression. In the case of lamivu-
dine, underlying disease such as chronic hepatitis
B as well as concomitant anti-HIV drugs may be
especially prevalent as confounding factors, and
causality has been difficult to establish [14].
Sirolimus has been used in solid organ transplan-
tation, but its side effect of hepatic artery throm-
bosis led to a black-box warning by the US Food
and Drug Administration [16].
Drugs may cause different kinds of liver dam-
age and histopathology may show a very heteroge-
neous pattern. Next to liver enzyme induction
(e.g., phenytoin, amiodarone) drugs may cause di-
rect liver toxicity with microvasular steatosis (e.g.,
valproic acid, tetracyclines), acute hepatitis with
hepatocellular swelling (e.g., isoniacid), cholestasis
(e.g., amoxicillin/clavulanic acid, chlorpromazine)
or eosinophilic inflammation (e.g., phenytoin) [17,
18].Allopurinol, halothane and carbamazepine are
known to cause granulomatous hepatitis [19, 20].
Causality must be viewed with circumspection
because of the potential for confounding. Patients
exposed to certain hepatotoxic drugs actually had
a lower mortality than non-exposed patients.This
might be interpreted as a protective effect of
drugs, and this could indeed be the case e.g., for
statins. A vast literature exists on the incidence re-
duction of cardiovascular disease and mortality by
statins [21, 22]. On the other hand, confounding
cannot be excluded since physician judgment
clearly plays a central role in selecting which pa-
tients will receive the drugs prescribed, and physi-
cians are likely to be most conservative in the pa-
tients at highest risk. The most striking example
was group L3D–, which had the highest mortality
of all groups but no drug exposure as studied here.
This suggests that physicians assess their patients
according to disease severity and are appropriately
reluctant to use potentially hepatotoxic medica-
tions in patients with the most severe liver disease
and greatest risk of death [23, 24]. Lower mortal-
ity in patients taking non-steroidal anti-inflamma-
tory drugs has been observed in several phar-
macoepidemiological studies, with a relative risk
reduction of 41% and a risk reduction of death by
26% [23, 24].These reductions remained after ad-
justment for age, gender, co-morbidity and poly-
pharmacy, and seem to be associated with physician
judgment [24].The most consistent finding in our
study was the high adjusted mortality in patients
receiving anticancer drugs and five individual
drugs. While one possibility for this association
are toxic drug effects, confounding by an underly-
ing life-limiting disease is more likely despite sta-
tistical adjustment for cancer diagnosis in our
study, or, in the case of opiates, their use in termi-
nal care [24].
In general, drug dosage schemes for patients
with chronic liver disease are badly needed, but
have been challenging to develop. This study
was intended as a preliminary step, to determine
whether particular drugs represent a significant
measurable risk. While only certain drugs could
be singled out as potentially harmful in patients
with CLD, it is clear that for patients whose un-
derlying liver disease was caused by drugs, the
consequences can be serious. In one study with
461 patients with drug related liver injury 53% of
patients had to be hospitalised and 18 (4%) suf-
fered fulminant liver failure of whom 12 died and
6 received a liver transplant [25]. In contrast to our
patients, in this study by Andrade et al chronic
liver disease was excluded. Acetaminophen alone
or in combination accounted for 49% of liver
transplantation cases in the UNOS database
1990–2002 [8]. However, the risks in patients with
known liver disease are less certain and measures
to reduce drug induced liver injury are urgently
needed.
We found that three readily accessible labora-
tory parameters – bilirubin, creatinine and INR –
could effectively stratify life expectancy for pa-
tients with CLD, even without computing the
MELD score. It has been suggested that other lab-
oratory parameters such as aspartate-aminotrans-
ferase predict mortality and the need for liver
transplantation in drug-induced liver disease [26].
We chose the MELD parameters since the score
has been widely implemented and used in different
clinical settings.MELD has been used primarily in
the context of single diseases and with rather low
patient numbers [3, 6, 7, 27]. We showed that
MELD can be used in large populations with dif-
ferent reasons for CLD to predict survival.
When large research databases are used, it is
important to scrutinise data quality. In our study
inclusion search results for drug exposure ap-
peared accurate, as were demographic data. Death
data files are controverted regarding timeliness
Discussion
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and accuracy. Sensitivity for mortality is reported
to be up to 92.1% with a specificity of 99.9% with
data from Social Security Administration Death
Master File (SSA DMF), as compared to >95%
with National Death Index as the gold standard
[11, 12, 28]. RPDR is updated monthly using SSA
DMF, which itself is updated weekly [12, 29].
Hence we cannot exclude slight inaccuracy during
the first and the last 1–2 months of the observation
period.
Our study has several limitations. Patient se-
lection may be influenced by the geographical area
where recruitment study sites are located. As an
example, 8.4% of our patients presented alcohol-
associated CLDwhereas Said et al found 29.9% of
patients with an alcohol-associated CLD in their
cohort[30]. Our study sites are located in the
greater Boston area, and thus the study results
may not be generalisable to other patient popula-
tions. Our study was designed to give an overview
of mortality of CLD patients with and without ex-
posure to potentially hepatotoxic drugs. The de-
sign of observational drug outcome studies has
been challenged [24]. Nevertheless, observational
studies have an important hypothesis-generating
role in pharmacoepidemiological research [31]. In
this study setting we did not analyse possible mor-
bidities caused by these prescription drugs, which
may have been considerable. Causality between
mortality and drug exposure was not established
here; in order to do so, in-depth studies of drug
exposure regarding duration and total amount will
have to be performed [18]. Although we used the
most probable covariates in the Cox regression
model, further confounding such as physician
judgment and over-the-counter (OTC) drug use
may still be present. In fact propensity scores have
been suggested in order to adjust for physician
judgment, but their use does not seem to influence
results substantially [32]. OTC drugs, especially
pain relievers such as acetaminophen or ibuprofen
may have influenced our study endpoints [33];
however, the majority of the observed drugs are
not available OTC. Some drug groups overlapped
and patients may have been exposed to more than
one drug; we therefore chose groups excluding
overlapping patients. Finally, laboratory thresh-
olds varied slightly among the study sites. Since
the differences were minute we do not believe
they are decisive for our study results.
In summary, we found in our observational
study that drug exposure overall was not associ-
ated with a higher mortality except in a few cate-
gories; in these, randomised controlled trials
should follow to analyse causality issues. Patients
with chronic liver disease have a high mortality
and the parameters bilirubin, creatinine and INR
per se may stratify these patients regarding mor-
tality.
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Appendix 1: Drug groups
A) Hepatic Metabolism (11 drugs). High ex-
traction drugs are typically flow dependent and
flow is diminished in cirrhosis. This implies that
the first pass effect of primarily flow dependent
drugs is reduced in CLD and the free serum levels
are higher than normal. ClHep = Q x E where
ClHep is the hepatic clearance of a drug, Q =
blood flow through liver and E = hepatic extrac-
tion of drug [1]. The following drugs have a high
hepatic extraction rate of >60% (= first pass effect)
in healthy humans and therefore show a clinically
relevant flow dependent hepatic metabolism re-
quiring dose reduction [1, 2]; oral formulations
were included wherever possible by excluding
search terms “solution”, “injection”, “mg/ml”,
“IV” and “vial” because of the hepatic first-pass ef-
fect involved (cyclosporine, fluorouracil, idaru-
bicin, lovastatin, morphine, pentazocine, queti-
apine, tacrolimus, verapamil, vinblastine, vincris-
tine).
B) Direct Liver Toxicity (9 drugs). A common,
dangerous and costly problem is direct drug toxic-
ity to the liver.Drugs like antiepileptics and tuber-
culostatics are used quite commonly. This group
contains iv and po drugs with known direct liver
toxicity: acetaminophen, amoxicillin-clavulanate,
carbamazepine, diclofenac, etoposide, ibuprofen,
isoniazide, propylthiouracil and valproic acid.
C) FDA Black BoxWarnings (BBW) for liver
toxicity (43 drugs) [3]. The FDA issues BBW to
give health care professionals a clear understand-
ing of serious side effects of a drug. 0.7% of out-
patients receive a prescription in violation of FDA
BBW [4]. Of these less than 1% has an ADE.The
following drugs are FDA listed for potential hepa-
totoxicity and were therefore included: adefovir
& dipivoxil, amiodarone, bosentan, dacarbazine,
danazole, dantrolene, daunorubicine (conven-
tional), didanosine, docetaxel, emtricitabine, ente-
cavir, epirubicin, felbamate, flutamide, gemtuzu-
mab, idarubicin, isoniazid, ketokonazole, lamivu-
dine, metformin, methotrexate, naltrexone,
nandrolone decanoate, oxandrolone and oxyme-
thalone (anabole steroids), nefazodone, nevirap-
ine, pemoline, sirolimus, stavudine, streptozocin,
telbivudine, telithromycin, tenofovir & disoproxil
fumarate, tipranavir, tolcapone, trovafloxacin, val-
proic acid, zalcitabine, zidovudine, zidovudine
& lamivudine.
D) Potentially hepatotoxic drugs included in
LMR (42 drugs). The following drugs were stud-
ied from March 24th 2003 to September 23rd
2003 and went live in the LMR warning system
for potential liver toxicity by January 1st 2004 in
all three hospitals studied. Warnings are triggered
by the combination of the drugs with the Public
Health Service (PHS) diagnosis codes for cirrho-
sis (81), ascites (889) or oesophageal varices (676)
as well as liver function tests. The following drugs
were included: acetazolamide, allopurinol, amio-
darone, atorvastatin, azathioprine, carbamazepine
(oral: chew, XR), cervistatin, chlorpropamide,
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clidinium bromide, clonazepam, colchicine ± pro-
benecid, cyclosporine (oral: Micro oral, Micro,
oral sol), danazol, dantrolene, disulfiram, dival-
proex sodium, ergotamine and caffeine combined,
ergotamine tartrate, erythromycine estolate,
ezetimibe and simvastatin (10–10/20/40/80 mg)
combined, fenofibrate, fluvastatin, gemfibrozil,
isoniazid, isoniazide and rifampin combined, iso-
niazide and rifampin and pyrazinamide combined,
levonorgestrel implants, lovastatin, medroxypro-
gesterone acetate, methazolamide, methyldopa,
naltrexone, nefazodone, phenelzine, pioglitazone,
pravastatin, pyrazinamide, rosiglitazone, simvasta-
tin, terbinafine, tranylcypromine, valproic acid,
warfarin sodium.
E) Functional drug classes: The group Statins
included lovastatin, atorvastatin, cervistatin, sim-
vastatin, ezetimibe and simvastatin combined and
fluvastatin, the group Antibiotics amoxicillin-cla-
vulanate, telithromycin, trovafloxacin and eryth-
romycine estolate. Antiepileptics enclosed car-
bamazepine, valproic acid, divalproex sodium and
felbamate. Opiates included morphine and penta-
zocine, Anti-cancer agents fluorouracil, flutamide,
gemtuzumab, dacarbazine, idarubicin, vinblastine,
vincristine, vinorelbine, etoposide, daunorubicine,
docetaxel and epirubicin. Immunosuppressants
embraced cyclosporine, tacrolimus, methotrexate
and sirolimus and HIV drugs emtricitabine, ade-
fovir & dipivoxil, didanosine, entecavir, lamivu-
dine, nevirapine, stavudine, telbivudine, tenofovir
& disoproxil fumarate, tipranavir, zalcitabine, zi-
dovudine as well as zidovudine and lamivudine
combined. TBC drugs encompassed isoniazide
and the two combinations isoniazide/rifampin as
well as isoniazide/rifampin/pyrazinamide.
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